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Current therapies for childhood T-cell acute lymphoblasticleukemia have increased survival rates to above 85% in devel-oped countries.  Unfortunately, some patients fail to respond to
therapy and many suffer from serious side effects, highlighting the need
to investigate other agents to treat this disease.  Parthenolide, a nuclear
factor kappa (κ)B inhibitor and reactive oxygen species inducer, has been
shown to have excellent anti-cancer activity in pediatric leukemia
xenografts, with minimal effects on normal hemopoietic cells.  However,
some leukemia initiating cell populations remain resistant to partheno-
lide.  This study examined mechanisms for this resistance, including pro-
tective effects conferred by bone marrow stromal components.  T-cell
acute leukemia cells co-cultured with mesenchymal stem cells demon-
strated significantly enhanced survival against parthenolide (73±11%)
compared to cells treated without mesenchymal stem cell support
(11±9%).  Direct cell contact between mesenchymal cells and leukemia
cells was not required to afford protection from parthenolide.
Mesenchymal stem cells released thiols and protected leukemia cells
from reactive oxygen species stress, which is associated with partheno-
lide cytotoxicity.  Blocking cystine uptake by mesenchymal stem cells,
using a small molecule inhibitor, prevented thiol release and significantly
reduced leukemia cell resistance to parthenolide.  These data indicate it
may be possible to achieve greater toxicity to childhood T-cell acute
lymphoblastic leukemia by combining parthenolide with inhibitors of
cystine uptake.
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ABSTRACT
Introduction
The introduction of contemporary therapies for childhood T-cell acute lym-
phoblastic leukemia (T-ALL) has resulted in remission rates that are closer to that
of B-cell precursor (BCP) ALL but survival rates remain lower and 15-20% of chil-
dren with T-ALL die from relapsed/refractory disease.1 Patients with high-risk dis-
ease or those who relapse often receive more intensive treatment, making them
more susceptible to toxicity and long-term secondary complications.2 This high-
lights the need to investigate other agents to treat this disease.
It has been demonstrated that numerous cancers generate high levels of reactive
oxygen species (ROS) compared to healthy tissue counterparts, where ROS levels
are normally maintained in a tightly controlled manner.3 In T-ALL, ROS levels have
been shown to be heightened, and this can inactivate phosphatase and the tensin
homolog (PTEN), promoting leukemia cell survival.4 In human T-ALL, ROS levels
are restrained by downregulation of protein kinase c theta (PKCθ) caused by
NOTCH-1, a commonly activated mutation in T-ALL.5 However, if ROS stress lev-
els are pushed above a certain threshold, cell death is forced to occur.3 Therefore,
ROS promoting drugs may be an effective way of targeting cancer cells.
Parthenolide (PTL) has been previously shown by ourselves and others to be a
promising therapeutic agent for blood cancers.6-8 Importantly, it has limited effects
on normal cells at the doses required to kill cancer cells.
PTL can target cancer cells via numerous mechanisms,
such as inhibition of nuclear factor (κ)B, p53 activation
and ROS stress.6,7 However, the mechanism of PTL toxici-
ty to T-ALL has not been defined.  
Parthenolide has been shown to be very effective
against childhood T-ALL in vivo, with elimination of the
disease and restoration of murine hemopoiesis in
NOD.Cg-PrkdcscidIl2rtm1Wjl/SzJ (NSG) mice.8 However, in
mice engrafted with different leukemia initiating cell pop-
ulations from 2 of 9 T-ALL cases, disease progression was
delayed rather than eliminated, indicating variable sensi-
tivity of certain subpopulations to PTL.  Reasons for the
differences in sensitivity may be due to the effect of the in
vivo microenvironment.  Bone marrow (BM) stromal cells
release cysteine for uptake by chronic lymphocytic
leukemia (CLL) cells, driving anti-oxidative glutathione
synthesis, which provides protection against ROS gener-
ating chemotherapeutic agents, such as fludarabine and
oxiplatin.9
Mesenchymal stem cells (MSC) are key constituents of
the BM microenvironment and have been shown to
enhance protection against certain drugs in T-ALL cell
lines10 and primary samples from patients with B-ALL,
acute myeloid leukemia (AML) and CLL.9,11-13 Co-culture of
T-ALL cell lines with MSC enhanced resistance to the
anthracycline idarubicin.10 However, the role of ROS in
stromal cell mediated protection in childhood ALL has not
been reported.  As we had previously reported resistance
to PTL in T-ALL cases, in this study the cytotoxic and ROS
inducing effects of the drug on primary T-ALL cells in the
presence of MSC were examined to increase our under-
standing of PTL resistance.
Methods
T-ALL and normal samples
Bone marrow samples from 10 children, aged 2-17 years
(median 5 years), diagnosed with T-ALL at presentation or
relapse were collected with informed consent and approval of
University Hospitals Bristol NHS Trust and London Brent
Research Ethics Committee (Table 1).  Mononuclear cells (MNC)
were separated via density gradient centrifugation using Ficoll-
Hypaque (Sigma-Aldrich, Gillingham, UK).  MNC were sus-
pended in 90% fetal calf serum (FCS, Thermo Scientific, Paisley,
UK) and 10% dimethyl sulfoxide (DMSO, Origen Biomedical,
Solihull, UK) and stored in liquid nitrogen prior to use.  Samples
from patients with a range of karyotypic abnormalities, diagnos-
tic age and minimal residual disease (MRD) status were investi-
gated. 
Bone marrow from a consenting healthy donor was used as a
source of MSC.  See the Online Supplementary Appendix for full
details of MSC expansion and characterization. 
Cytotoxicity assays
T-cell acute lymphoblastic leukemia cells were plated in dupli-
cate (for each drug concentration tested) at 1.2x105 cells/mL in
RPMI 1640 medium (Sigma-Aldrich) containing 20% FCS, 1% L-
glut and 1% Pen/Strep, hereafter referred to as suspension medi-
um.  Drugs used for assays were: PTL (Enzo Life Sciences,
Exeter, UK) at 1-10 μM, N-acetyl cysteine (NAC, Sigma-Aldrich)
at 15 mM and 30 μM, and sulfasalazine (SSZ, Sigma-Aldrich) at
300 µM, all prepared in suspension medium. For co-culture
experiments, 5x104 MSC/mL were seeded per well and left to
adhere for 24 hours (h).  MSC medium was removed and
replaced with suspension media containing 1x105 T-ALL
cells/mL.  T-ALL cells were left to settle for 1 h and then treated
with 10 μM PTL with or without 300 μM SSZ, for 24 h.  After
treatment, non-adherent cells were removed and stained with
annexin-V conjugated to fluorescein isothiocyante (Miltenyi
Biotec) for 10 minutes (min).  Cells were washed and stained
with propidium iodide (PI, Miltenyi Biotec) prior to flow cyto-
metric analysis. See Online Supplementary Figure S1 for details. 
For transwell separation experiments, 1x105 MSC/mL were
seeded per well in MSC media and left to adhere for 24 h.  MSC
medium was removed and replaced with suspension medium.
T-ALL cells were seeded at 2x105 cells/mL onto Costar Transwell
inserts (0.4 μM pore size, Corning Life Sciences, Ewloe, UK)
above the adherent MSC.  T-ALL cells were left to settle for 1 h
and then treated with PTL with or without SSZ for 24 h.  After
treatment, cells in transwell inserts were removed and viability
was assessed by flow cytometry, as above.
Reactive oxygen species detection 
Cells were treated with 5 μM of the redox sensitive probe 5-
(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein di-
acetate (CM-H2DCFDA, Thermo Fisher Scientific) for 30 min at
37°C.  Cells were treated with PTL, then immediately analyzed
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Table 1. Patients’ sample characteristics.
Patient N. Karyotype Sex Age (years) Disease status at biopsy MRD risk statusa
1 46XY M 7 Diagnosis Risk
2 t(1;14) M 3 Diagnosis Risk
3 46XY M 17 Diagnosis High
4 t(8;14) M 3 Diagnosis Low
5 t(11;14), add(17) M 2 Relapse High
6 Runx1 rearr M 3 Diagnosis N/A
7 46XY M 6 Diagnosis Low
8 add (4), add (9) M 14 Diagnosis High
9 del (4), del (9) M 9 Diagnosis Low
10 add (7), add (9), add (14) M 4 Diagnosis Low
All patients treated on UKALL2011 protocol, except patients 3, 5 and 8 who were treated on UKALL 2003. aMinimal residual disease (MRD) risk status at Day 29, on respective
treatment protocols.  N: number; M: male.
over a 90 min period by staining with PI and measuring the
median fluorescence intensity (MFI) of the ROS probe by flow
cytometry.
Reduced glutathione detection 
The level of reduced glutathione (rGSH) was detected using
the GSH/GSSG-Glo luminescence assay using a plate reader
(GloMax, both Promega, Chilworth, UK).  Levels of rGSH were
quantified in 2x104 live T-ALL cells either untreated or treated
with 10 μM PTL for 1 h.
Thiol detection 
The thiol concentration in media was detected using a 5,5′-
dithiobis-(2-nitrobenzoic) (DTNB) assay.  MSC were plated at
5x104 cells/mL per well in MSC medium and allowed to adhere
for 24 h.  MSC medium was replaced with suspension medium
and left for 24 h.  Subsequently, 25 μL of MSC conditioned sus-
pension medium was removed and mixed with 100 μL TRIS
buffer (0.1M) and 25 μL DTNB (2.5mM, Sigma-Aldrich) solu-
tion.  The reaction was left for 10 min at room temperature, then
the absorbance read at 412nm.  The concentration of thiols was
quantified using a linear regression equation of the standard
curve generated from the absorbance of known standards of cys-
teine.
Cysteine transporter, xCT, knockdown in MSC
Higher thiol levels are a feature of cysteine, which is usually
synthesized using a specialized amino acid transport system,
known as the xc- system.  To investigate whether knockdown of
the cysteine transporter, xCT, in MSC affected thiol production
small interfering RNAs (siRNAs) for xCT and a non-coding
scramble control were transfected into MSC with Lipofectamine
3000 (all Thermo Fisher Scientific) using 20nM siRNA.  MSC
were plated at 5x104 cells/mL per well in MSC media, without
Pen/Strep, containing siRNA for 24 h.  MSC media was com-
pletely removed and replaced with DMEM containing 10% FCS
for 24 h.  To assess xCT knockdown, mRNA and protein were
harvested using a PARIS kit (Thermo Fisher Scientific).  (See
Online Supplementary Appendix for details.) 
Statistical analysis
Full details of statistical analyses are provided in the Online
Supplementary Appendix.
Results
Cytotoxicity is linked to changes in ROS and GSH
Eight of 10 samples responded to treatment with PTL,
with a median half-maximal inhibitory concentration
(IC50) of 7.6 μM (range 2.6-10.0 μM).  The highest dose of
PTL reduced the viability of samples to an average of
30±18% compared to untreated cells (Online
Supplementary Figure S2A).  Two cases (patients 3 and 9)
were relatively resistant to PTL with viabilities remaining
above 55% at the highest dose tested (Online
Supplementary Figure S2B).  To measure ROS levels, cells
from 4 samples were pre-incubated with the ROS sensi-
tive probe CM H2DCFDA and then treated with PTL.
After 30 min, the level of ROS stress was significantly
higher in PTL treated cells and it was 5-fold higher than
untreated cells after 90 min (P≤0.02) (Figure  1A).  Addition
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Figure 1. Parthenolide (PTL) induces changes in reactive oxygen species (ROS) and reduced
glutathione (rGSH)  levels can be reversed by N-acetyl cysteine (NAC). (A) T-cell acute lym-
phoblastic leukemia (T-ALL) samples (patients 1, 3, 5, and 9) were pre-incubated with the ROS
sensitive probe CMH2DCFDA and ROS accumulation was measured in live cells over 90 min-
utes by flow cytometry in response to 10 μM PTL or with PTL+15 mM NAC.  Fold change in
median fluorescence intensity (MFI) compared to untreated cells is shown; data represent 
mean ± Standard Deviation (SD). Asterisks represent significant differences between PTL and
PTL+15 mM NAC.  (B) Dose response curve of patient samples 2, 5, 8, and 10 that had been
treated with PTL only (1-10 μM), PTL+30 μM NAC, or PTL+15mM NAC; data represent
mean±SD.  Top row of asterisks represent significant differences between PTL alone versus
PTL+15mM NAC; bottom row of asterisks represent significant differences between PTL alone
versus PTL+30 μM NAC.  (C) GSH levels were measured in T-ALL samples (patients 1-9) after
treatment with PTL (10 μM) for 1 hour and compared with those in untreated cells.  Symbols
represent the mean % change from untreated cells in replicate samples.  Each symbol repre-
sents an individual patient (see Online Supplementary Figure S1 for patient symbol key).  Lines
represent median and interquartile range.  Results were analyzed by two-way ANOVA (A and B)
or paired t-test (C).  *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001.
A B
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of the antioxidant NAC to PTL treated cells caused a com-
plete block in PTL induced ROS stress over the 90-min
period (P≤0.02) (Figure  1A).  NAC (15 mM) reversed PTL
induced cytotoxicity, even at the highest dose (10 μM),
where T-ALL cells retained a viability of 110±22% com-
pared to 6±3% in cells treated with PTL alone (P≤0.0001)
(Figure  1B).  A lower dose of NAC, 30 μM, also signifi-
cantly reduced PTL cytotoxicity (P≤0.01), increasing the
IC50 from 2.3 μM to 5.7 μM.  As a further measure of
oxidative changes, the levels of the anti-oxidative mole-
cule rGSH were measured in PTL treated cells from sam-
ples 1-9.  The levels of rGSH detected after 1 h were sig-
nificantly lower in PTL treated cells with a median of 12%
(range 0-58%) compared to untreated cells (P=0.02)
(Figure  1C). rGSH levels were higher in the PTL resistant
cases (patients 3 and 9).
MSC protection from PTL and ROS stress
Mesenchymal stem cells  generated from normal BM
cells were highly positive for MSC associated markers;
CD73 (99±0.3%), CD105 (90±3%), CD90 (99±0.2%) with
low expression of hemopoietic cell markers CD45
(0.3%±0.2%) and CD34 (0.6±0.5%).  MSC protected T-
ALL cells from the cytotoxic effects of PTL (78% median
survival, range 57-84) in co-culture compared to 8% (range
2-26%) without MSC (P=0.002) (Figure  2A).  When T-
ALL cells were seeded onto transwell inserts to prevent
direct cell contact with MSC, median survival following
treatment (58%, range 20-71%) was significantly higher
compared to cells treated without MSC support (P=0.03).
However, T-ALL survival in transwell cultures was lower
than cells in direct contact with MSC (P=0.02) (Figure  2A).
To ascertain whether this MSC conferred resistance to
PTL is retained on removal from the supportive environ-
ment, T-ALL cells that had been pre-conditioned with
MSC for 24 h were treated with PTL without further MSC
support.  Pre-conditioned cells showed some evidence for
enhanced survival compared to cells without conditioning
with an increase in IC50 from 2.6 to 3.3 μM.  The increase
in PTL resistance in MSC conditioned cells was modest
but significant (P=0.04) (Online Supplementary Figure  S3).
As ROS levels are associated with PTL cytotoxicity, the
ability of MSC to modulate ROS levels was investigated.
T-ALL cells conditioned with MSC had significantly lower
levels of ROS stress, (ROS MFI 234, range 67-380), com-
pared to those without MSC conditioning (313, range 156-
506; P=0.02) (Figure 2B).  When T-ALL cells were treated
with PTL, ROS levels were significantly increased in both
MSC conditioned (P=0.04) and unconditioned (P=0.01)
cells. However, the ROS levels following PTL treatment
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Figure 2. Mesenchymal stem
cells (MSC) protect T-cell acute
lymphoblastic  leukemia (T-
ALL) cells from parthenolide
(PTL)-induced cell death, reac-
tive oxygen species (ROS)
stress and decreased reduced
glutathione (rGSH)  levels.  (A)
The viability of T-ALL samples
(patients  1, 2, 5, 6, and 10)
after 24 hours (h) of PTL treat-
ment (10 μM) with or without
MSC in  direct contact and in
transwells.  (B) ROS levels in
patient samples 2, 5, 6, 9, and
10 after 1 h PTL treatment (10
μM) with or without MSC.  (C)
The concentration of rGSH in
patient samples 2, 5, 6, 9, and
10 after 1 h PTL treatment (10
μM) with or without  MSC.
Symbols represent the average
value in replicate samples.
Each symbol  represents an
individual patient.  Lines repre-
sent median and interquartile
range.  (D) Increase in thiol con-
centration in media from MSC
culture after 24 h compared to
blank media (n=6).  Thiol con-
centrations were derived from
the standard curve of known
cysteine levels.  Results were
analyzed by one-way ANOVA (A-
C) or paired t-test (D). *P≤0.05,
**P≤0.01, ***P≤0.001.  
BA
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were significantly lower in MSC conditioned cells (353,
range 200-617) compared to those cultured without MSC
(573, range 321-796; P=0.05) (Figure  2B).  
To examine whether these observed protective effects
were specific to MSC, T-ALL cells were co-cultured on
BM stromal cells and fibroblasts.  PTL toxicity was
reduced in co-cultures containing stromal cells and fibrob-
lasts but not to the same extent as cultures containing
MSC (Online Supplementary Figure  S4A).  T-ALL cells con-
ditioned with stroma had similar ROS levels to those con-
ditioned with MSC.  ROS levels in cells cultured on
fibroblasts were similar to those observed in unsupported
cultures (Online Supplementary Figure  S4B).
Parthenolide  is known to lower rGSH levels in
leukemia cells, therefore the ability of MSC to modulate
this effect was examined.  T-ALL cells conditioned with
MSC had significantly higher levels of rGSH (median
131nM, range 108-135nM) compared to those without
conditioning (82nM, range 60-99nM; P=0.03).  Following
PTL treatment, rGSH levels were significantly decreased
in both MSC conditioned (P=0.04) and unconditioned
(P=0.0003) cells, indicating reduced anti–oxidant activity.
However, rGSH levels were still higher in MSC condi-
tioned cells (median 87nM, range 66-117nM) compared to
those without MSC conditioning (26nM, range 7-35nM;
P=0.01) (Figure  2C). 
As cysteine is crucial for GSH synthesis in leukemia, it
is possible that MSC release cysteine into the surrounding
media, thereby moderating the anti-oxidant effects of
PTL.  A thiol detection assay was used, since cysteine con-
tains a free thiol group, to investigate cysteine release.
Thiol concentrations were significantly higher in media
removed from MSC cultures (91±17 μM) compared to
background media levels (62±17 μM; P=0.0002), repre-
senting a 1.5-fold increase over background (Figure  2D).
Blocking thiol release overcomes protective effect
The thiol functional group plays a major role in intracel-
lular anti-oxidant defenses.  Cysteine residues eliminate
ROS, usually by converting them to 2H2O or H2O and O2,
and reduce oxidized protein thiols.14 SSZ, an inhibitor of
the cystine uptake antiporter xc-, was used to inhibit cys-
tine uptake and block subsequent cysteine generation and
release in MSC, to determine what effect this would have
on the protection conferred by MSC.  The combination of
PTL and SSZ significantly reduced the median viability of
T-ALL cells with MSC conditioning to 38% (range 11-
42%) compared to PTL (71%, range 59-95%; P=0.002) or
SSZ alone (88%, range 69-109%; P=0.04) (Figure  3A).
The treatment combination reduced viabilities to levels
comparable to those observed in cells treated with both
agents without MSC conditioning (16%, range 5-24%).  In
the absence of MSC, SSZ had low cytotoxicity (92%
median survival, range 77-102%) and when combined
with PTL there was no significant difference in toxicity
compared to PTL alone (P=0.9).  Addition of PTL+ SSZ to
T-ALL cells conditioned with BM stroma or fibroblasts
also reduced leukemia cell survival, although to a lesser
extent (Online Supplementary Figure  S4C).  Interestingly,
the effects of combining these agents were more remark-
able in samples that were relatively resistant to PTL.  Fifty-
six percent of cells from patient 9 survived treatment with
PTL, but viability was reduced to only 6% when PTL was
combined with SSZ.  Leukemia burden in NSG mice
engrafted with this sample was significantly reduced
when treated with PTL and SSZ compared to placebos
Improving T-ALL sensitivity to parthenolide
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Figure 3. Combination of parthenolide (PTL) with sulfasalazine (SSZ) overcomes
protective effects of mesenchymal stem cells (MSC). (A) Viability of acute lym-
phoblastic leukemia (ALL)  samples (patients 2, 5, 6, 9, and 10) treated with PTL (10
μM), SSZ (300 μM) or a combination of both agents for 24 hours (h) with or without
MSC. (B) Viability of samples (patients 1, 2, 5, 6, and 10) following 24-h exposure to
PTL (10 μM) or a combination of PTL with SSZ (300 μM) separated from MSC by tran-
swell inserts.  Symbols represent the average viability in replicate samples.  Each
symbol represents an individual patient.  Lines represent median and interquartile
range. (C) Thiol concentration in media following incubation with MSC with or without
SSZ treatment (n=4).  Data represent mean±Standard Deviation.  Results were ana-
lyzed by one-way ANOVA (A) or paired t-test (B and C).  *P≤0.05, **P≤0.01.
A B
C
(P<0.0001) (Online Supplementary Figure S5).  Using SSZ
alone and in combination with PTL had minimal effects
on normal hemopoietic cells (Online Supplementary Figure
S6).  
In transwell experiments, using SSZ with PTL abrogated
the protective effects of MSC support, reducing T-ALL
survival from 58% (range 20-71%) to 14% (range 9-43%;
P=0.01) (Figure  3B).  Media harvested from cultures of
SSZ treated MSC contained thiol levels similar to back-
ground media (53±19 μM vs. 61±10 μM, respectively).  In
contrast, media from untreated MSC contained signifi-
cantly higher thiol levels (90±11μM; P=0.005) compared
to media from SSZ treated cells, representing a 1.5-fold
increase over background media (Figure  3C). 
As a second approach to block the cystine uptake
antiporter xc-, and thereby prevent cysteine release from
MSC, xCT was targeted with siRNAs. Relative gene
expression levels of xCT were significantly lower in MSC
48 h after transfection with either siRNA 1 (17±9%) or
siRNA 2 (9±4%) compared to scramble control siRNA
(P≤0.0001) (Online Supplementary Figure S7A).  Protein
available from xCT siRNA-1 showed a significant reduc-
tion in xCT expression (3±0.1%) relative to scramble con-
trol levels quantified by western blotting densitometry
(P=0.002) (Online Supplementary Figure S7B).  
The viability of PTL treated T-ALL cells, co-cultured
with MSC treated with xCT siRNA-1 (27%, range 3-28%)
or -2 (35%, range 24-42%), was significantly lower than
cells co-cultured with scramble control MSC (49%, range
46-72%; P<0.05) (Figure  4A).  As siRNA-1 provided the
best reduction in MSC protection, it was selected for fur-
ther experiments.  When transwell inserts were used to
separate xCT knockdown MSC from T-ALL cells, the
median viability after PTL treatment was significantly
lower (13%, range 7-30%) compared to scramble control
MSC cells (24%, range 15-74%; P=0.05) (Figure  4B).
Scramble control MSC media had a significantly higher
thiol concentration (86±2 μM) compared to media har-
vested from xCT knockdown MSC (46±1 μM; P=0.002)
(Figure  4C).  Media from xCT knockdown MSC did not
show any increase in thiol levels above background media
(53±1 μM).
To confirm that the observed effects of interfering with
xCT were a result of blocking cystine uptake, and not a
result of toxicity, the viability and morphology of treated
MSC were assessed.  Treatment with PTL, SSZ or both
agents in combination had no effect on the viability and
confluency of MSC (P≥0.37) (Figure  5A) nor did siRNA
treatment (P≥0.82) (Figure  5B and Online  Supplementary
Figure  S8).  This was also confirmed by flow cytometry
(Figure  5C).
Discussion
To date, PTL is the only drug that has been shown to be
capable of completely eradicating childhood ALL in NSG
xenografts, as a single agent.8 Most studies, using such
models, report reduction in leukemia burden but levels
often increase on cessation of treatment.  Consequently,
there is much interest in the application of PTL for cancer
therapy. Several groups are developing strategies to
improve the bioavailability of PTL, without having detri-
mental effects on its pharmacokinetic properties.15-19 PTL
can be successfully sequestered into nanoscopic vectors
which can achieve equivalent toxicity to unmodified PTL.16-
18 Nanoparticle PTL formulations can be used in vivo at 40-
fold lower doses with 20-fold lower administration fre-
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Figure 4. xCT knockdown in mesenchymal stem cells (MSC) overcomes
MSC mediated resistance to parthenolide (PTL). Viability of T-cell acute
lymphoblastic  leukemia (T-ALL) samples (patients 5, 6, 8-10) treated with
10 μM PTL for 24 hours (h)  in the presence of MSC pre-treated with xCT
or scramble control siRNA, in direct contact (A) or samples (1, 2, 6, 8, and
10) in transwell inserts (B).  Symbols represent the average viability in
duplicate samples.  Each symbol represents an individual patient.  Lines
represent median and interquartile range.  (C) Thiol concentration in
media following 24-h incubation with MSC pre-treated with xCT or scram-
ble control siRNA compared to background media.  Data represent
mean±Standard Deviation. (n=4).  Results were analyzed by one-way
ANOVA (A) or paired t-tests (B and C).  *P≤0.05, **P≤0.01.
A B
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quency than standard PTL.16 Some of these delivery sys-
tems are inexpensive and formulations are readily scalable.18
Consequently, they should facilitate the use of PTL at clin-
ically relevant doses. However, the efficacy of many thera-
peutic drugs may be compromised by the host BM
microenvironment.  Therapy-induced niches, which pro-
tect leukemia cells against standard first-line induction
agents, have been described in ALL.12,20 In the present study,
we investigated whether resistance to PTL, reported in a
minority of T-ALL cases,8 may be conferred by BM-derived
MSC.  
In vitro PTL treatment reduced viability of T-ALL cells to
less than 30%, confirming previous results in a separate
cohort of pediatric cases.8 While there were differences in
the responses of individual patient samples, there was no
correlation between PTL cytotoxicity with karyotype or
MRD risk status, which may be a result of the heteroge-
neous nature of this disease.  PTL was shown to increase
ROS stress and lower rGSH levels in T-ALL.  The anti-
oxidative compound NAC blocked ROS upregulation and
diminished PTL cytotoxicity, suggesting that PTL toxicity
is, at least in part, related to ROS stress in T-ALL.  These
findings concur with reports of increased ROS stress in pri-
mary AML and CLL cell lines following PTL treatment.6,21,22
The protective effect provided by NAC may be attributed
to the role of cysteine as the rate limiting amino acid in
rGSH production.23 Reduction of cystine to cysteine and
subsequent supply to leukemia cells is crucial for GSH syn-
thesis in these cells.  GSH levels elevate the anti-oxidative
capacity of cells, which may provide protection against
PTL.  In AML and breast cancer, populations of cells endure
lower levels of ROS stress and these cells are more resistant
to therapy.24,25 It is unclear whether ROS is actively elimi-
nated by rGSH or if PTL directly interacts with rGSH, lead-
ing to a reduction in anti-oxidative capacity and increased
ROS accumulation.  One function of rGSH is to detoxify
cells from reactive electrophiles,26 which PTL contains in the
form of an a,β-unsaturated carbonyl group.  PTL can direct-
ly interfere with rGSH synthesis in AML, causing depletion
of rGSH, allowing ROS levels to increase.21 Whether PTL
directly blocked rGSH synthesis was beyond the scope of
this study.  However, it is evident that ROS levels increased
and rGSH levels dropped, putting the cells under higher lev-
els of stress, which is likely to drive apoptosis.
As these data indicate that ROS levels may be linked to
PTL cytotoxicity, it is possible that the BM microenviron-
ment provides resistance to drug activity by protecting
leukemia cells from ROS stress.  CLL cells had decreased
sensitivity to the ROS inducing agents fludarabine and oxi-
platin when co-cultured with BM stromal cells.9 Chemo-
protection was derived from the generation and release of
cysteine by stromal cells for uptake by CLL cells.  The BM
microenvironment can also play a role in leukemia drug
resistance, mediated by a diverse set of mechanisms, both
by direct cell adhesion11,13,27 and/or soluble factor
release.12,20,28,29 In this study, the protective effects of MSC
against PTL toxicity were related to decreases in ROS stress
and preserved rGSH levels, suggesting that MSC increased
the anti-oxidative stress capacity of T-ALL cells and thereby
conferred resistance to PTL.  To eliminate variability, MSC
were generated from a single normal BM donor, allowing
direct comparison of the effects on the patients' samples.
This may have introduced bias but our results are consis-
tent with those reported in CLL.9 These data also suggest
that protection is provided by one or more secretable fac-
tors, as preventing direct contact with MSC still provided T-
ALL cells with protection against PTL.  However, protection
was not to the same extent as observed in direct contact,
suggesting involvement of other factors.
Mesenchymal stem cell conditioned media contained sig-
nificantly higher levels of thiols, an important feature of the
anti-oxidative compound cysteine, compared to uncondi-
tioned media.  A key mechanism by which normal cells
synthesize cysteine is via intake of extracellular cystine
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Figure 5. Effects of parthenolide (PTL) and xCT modifying agents on mesenchymal stem
cell (MSC) viability. (A) Average live MSC counts from 3 fields (x10 magnification) following
treatment with PTL (10 μM), sulfasalazine (SSZ) (300 μM), or a combination of both agents
measured by fluorescence microscopy.  (B) Average live MSC counts from 3 fields (x10 mag-
nification) following treatment with PTL (10 μM), pre-treated with xCT, or scramble control
siRNA.  (C) Viability of MSC following treatment with PTL (10 μM) and SSZ (300 μM), or PTL
after pre-treatment with xCT siRNA, measured by flow cytometry.  Treatment with 70%
ethanol served as a positive control for inducing toxicity.  Data represent mean±Standard
Deviation (n=3).  Live cell counts by fluorescence microscopy were calculated using the
ImageJ particle analysis software. Results were analyzed by one-way ANOVA (A-C).
***P≤0.001.
A B
C
using a specialized amino acid transport mechanism known
as the xc– system.14 The system specifically mediates cys-
tine and glutamate exchange across the cell membrane and
is comprised of two subunits: the light chain transporter
subunit SLC7A11 (or xCT) and the heavy subunit SLC3A2
(4F2hc).30,31 Cysteine is unstable outside of cells and is rap-
idly oxidized to form a disulphide bridge with another cys-
teine amino acid, forming cystine.  However, upon entry
into the cell, cystine enters a stronger reducing environment
and is converted into cysteine.  Blocking xc–activity with a
small molecule inhibitor, SSZ,32 or by knockdown of the xc–
light chain component xCT, prevented thiol release and sig-
nificantly reduced MSC protection to levels close to those
observed in cells without MSC support.  In addition,
leukemia cell survival in a PTL resistant case was signifi-
cantly decreased when SSZ or xCT siRNA were used to
block xc– activity.  Furthermore, PTL and SSZ treatment in
vivo resulted in significantly reduced leukemia burden in
engrafted NSG mice compared to controls.  Similar results
have been reported in BCP-ALL, where cell viability was
diminished in a subset of patients following treatment with
cysteine dioxygenase, which catalyzes conversion of cys-
teine into cysteine sulfinic acid, thereby bypassing GSH
synthesis.33 Together, these findings indicate that MSC
release cysteine, which confers a survival advantage on
leukemia cells. The functional contribution of thiols was
further confirmed by the demonstration that T-ALL cells
exposed to the thiol containing compound NAC, at an
equivalent thiol concentration to that in MSC conditioned
media, were more resistant to PTL.  The fact that there was
still a small protective effect against PTL after interfering
with the xc- system, indicates that cysteine release may not
be the sole protective mechanism in these experiments.  A
recent study found that ALL cells release extracellular vesi-
cles that can be taken up by MSC, causing a shift to glycol-
ysis metabolism.  The switch to glycolysis led to an
increased release of the metabolite lactate, which might be
used as an additional source of energy by leukemia cells and
confer chemoresistance.34
While MSC are a fundamental component of the BM
niche, and contribute to its formation in vivo, other stromal
cells may have a role in leukemia maintenance and protec-
tion from therapeutic agents. We demonstrated that BM
stromal cells and fibroblasts also conferred protection
against PTL.  ALL cells themselves can alter the endosteal
and vascular compartments of the niche12 and induce apop-
tosis of osteoblast cells.17 The remodelled niche is dynami-
cally transient and on exposure to chemotherapeutic
agents, ALL cells can release CCL3 and cytokines TGF-β1
and GDF15, conferring chemoresistance by activating the
TGF-β signaling pathway.12 It may be possible to overcome
this resistance by disrupting the interactions between
leukemia cells and the BM environment.  
This is the first report demonstrating MSC provide a
protective effect to T-ALL cells against PTL.  Moreover, we
have shown that targeting the xc- system can overcome
this effect (see overview in Figure 6), adding to the evi-
dence that targeting xc– enhances the efficacy of anti-can-
cer agents in leukemias9 and in several solid cancer mod-
els.35-38 MSC viability was unaffected by PTL and targeting
xc-, so damage to this important element of the BM envi-
ronment39,40 should be minimal.  A logical progression of
this work will be determining whether the effects of PTL,
or indeed current chemotherapeutic agents, in vivo can be
enhanced using an xc- inhibitor like SSZ.  Furthermore,
with developments in nanoscopic drug delivery vectors, it
may be possible to use dual loaded (PTL+SSZ) nanovec-
tors to overcome selective patient resistance towards one
drug and the chemoprotective effects of the leukemia
microenvironment in vivo.
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Figure 6. Proposed mechanism of
action of parthenolide (PTL) and
the protective effect provided by
mesenchymal stem cells (MSC).
PTL causes apoptosis by increas-
ing reactive oxygen species (ROS)
stress and decreasing reduced
glutathione (rGSH)  resulting in
death of T-cell acute lymphoblas-
tic leukemia (T-ALL) cells (A).  MSC
express high levels of the cystine
glutamate antiporter xc-, facilitat-
ed by the antiporter protein xCT.
Extracellular cystine is taken up by
MSC and reduced into cysteine.
Cysteine is released into the extra-
cellular space for uptake by T-ALL
cells, blocking ROS induction and
preventing apoptosis (B). Blocking
the xCT system using sul-
fasalazine  (SSZ) or siRNA reduces
protective effects provided by MSC
(C).
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